Merck's Keytruda meets OS, PFS endpoints in first-line NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab (MK-3475) met the co-primary endpoints in the Phase III KEYNOTE-189 trial as first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).

An interim analysis of the 614-patient trial by an IDMC showed that Keytruda plus Alimta pemetrexed and cisplatin or carboplatin significantly improved overall survival (OS) and progression-free survival (PFS) vs. Alimta and cisplatin or carboplatin alone. Merck plans to present the results at an upcoming medical meeting...